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ABSTRACT
Mixed-lineage leukemia (MLL) maintains the expres-
sion of cellular memory genes during development,
while leukemic MLL fusion proteins aberrantly
maintain expression of hematopoietic stem cell
program genes such as HOXA9 to cause leukemia.
However, the molecular mechanism of gene activa-
tion is unclear. Here we show that only two func-
tional modules are necessary and sufficient for
target recognition: those that bind to non-
methylated CpGs and di-/tri-methylated histone H3
lysine 36 (H3K36me2/3). An artificial protein
composed of the two targeting modules and an
interaction domain for AF4-family coactivators can
functionally substitute for MLL fusion proteins.
Because H3K36me2/3 markers are indicative of
active transcription, MLL fusion proteins target
previously active CpG-rich genes and activate tran-
scription by recruiting coactivators thereto. Our
results indicate that such chromatin context-
dependent gene activation is the fundamental
mechanism by which MLL fusion proteins main-
tain the expression of the cellular memory/
hematopoietic stem cell program genes.
INTRODUCTION
TheMLL gene encodes an epigenetic regulator that main-
tains HOX gene expression during embryogenesis (1).
HOX genes are so-called cellular memory genes because
their expression is maintained throughout the develop-
ment. In the hematopoietic lineage, the MLL protein
(also known as HRX, MLL1 and KMT2A) activates the
transcription of posterior HOXA genes (e.g. HOXA7-A10)
(2,3). Posterior HOXA genes are hematopoietic stem cell
(HSC) program genes (4) that promote the self-renewal of
HSCs/immature progenitors (5). In normal hematopoiesis,
their expression is maintained by MLL in the HSC/
immature progenitor compartments, which diminishes as
cells differentiate. Chromosomal translocation generates
MLL fusion genes, whose products constitutively
activate the posterior HOXA genes, which results in
aberrant self-renewal of hematopoietic progenitors,
leading to leukemia (6). However, the precise molecular
mechanism by which MLL and MLL fusion proteins
activate their target genes remains unclear. MLL fusion
proteins exert their oncogenic functions as a complex with
the lens epithelium-derived growth factor (LEDGF) (also
known as PSIP1) (7). Disruption of Psip1 in mice causes
homeotic skeletal transformation, a characteristic pheno-
type caused by dysregulation of Hox gene expression (8).
LEDGF also facilitates the specific integration of the HIV
genome into transcriptionally active regions, presumably
by tethering the HIV genome/integrase complex with tran-
scriptionally active chromatin (9,10). In leukemia, MLL
frequently fuses with the ALL1-fused gene from chromo-
some 4 (AF4)- and eleven-nineteen leukemia (ENL)-family
genes, whose protein products are the components of
a transcriptional coactivator, termed AEP (the AF4
family/ENL family/PTEFb complex) (11–14). MLL
fusion proteins constitutively recruit AEP components
to activate transcription through direct interaction (e.g.
MLL-ENL) or by an as-yet-uncharacterized indirect
mechanism (e.g. MLL-AF6) (14). These previous studies
postulate that MLL fusion proteins recognize their target
genes through the MLL portion and constitutively recruit
the AEP coactivator through the fusion partner portion.
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Here, we report that MLL fusion proteins recognize a
specific chromatin context to activate cellular memory
genes. Our structure/function analyses demonstrate that
MLL fusion proteins recognize their target genes
through two functional domains: the PWWP domain of
LEDGF and the CXXC domain of MLL that specifically
bind to H3K36me2/3 and non-methylated CpGs, respect-
ively. Because H3K36me2 and H3K36me3 are generally
linked to gene activation (15,16), a previously transcribed
gene containing non-methylated CpGs in its promoter is
subjected to transcriptional activation by MLL fusion
proteins. These studies provide a novel chromatin
context-dependent gene activation mechanism by which
MLL fusion proteins maintain cellular memory.
MATERIALS AND METHODS
Cell culture
The human leukemia cell line ML-2 was cultured in RPMI
1640 medium supplemented with 10% fetal calf serum and
non-essential amino acids. 293T, plat-E and HeLa cells
were cultured in Dulbecco’s modified Eagle’s medium sup-
plemented with 10% fetal calf serum and non-essential
amino acids.
Vector construction
The pMSCV-neo MLL-ENL, PME (7) and Bcl2-
ires-E2A-HLF (17) vectors are described elsewhere.
Various MLL fusion constructs were generated by restric-
tion enzyme digestion or polymerase chain reaction
(PCR)-based mutagenesis. The cDNAs were cloned into
the pMSCV neo vector (for virus production) (Clontech,
Mountain View, CA) or the pCMV5 vector (for transient
expression). The expression vectors for FLAG-tagged
GAL4 fusion proteins were constructed by PCR using
pM (Clontech) as template and cloned into the pCMV5
vector. Various LEDGF constructs were generated by
PCR-based mutagenesis and cloned into the pcDNA4
HisMax vector (Invitrogen, Carlsbad, CA).
Western blotting
Western blotting was performed as described elsewhere
(14). The antibodies used in this study have been listed
in Supplementary Table S2.
Reverse transcription-PCR
RNAs were prepared using the RNeasy kit (Qiagen,
Valencia, CA) and reverse-transcribed with the
Superscript III first strand cDNA synthesis kit with
oligo(dT) primers (Invitrogen). Expression of PCE was
confirmed by regular PCR using the primer pair 50-AGA
ATTCGATATCGGAAACATGACTCGCGATTTCAA
ACC-30/50-TCACGTGTTCGCGATGCGACGGGCTTT
CGTGGAGGAG-30. Quantitative PCR (qPCR) for other
genes was performed as described previously (14) using
TaqMan probes [Gapdh (Mm99999915_g1), Hoxa7
(Mm00657963_m1), Hoxa9 (Mm00439364_m1), Hoxa10
(Mm00433966_m1), Cbx5 (Mm00483092_m1), Myb
(Mm00501741_m1) and Hmgb3 (Mm01377544_gH)
(Applied Biosystems)]. The expression levels, normalized
to Gapdh, were estimated using a standard curve and the
relative quantification method, as described in ABI User
Bulletin #2.
Virus production
The ecotropic retrovirus was produced using plat-E
packaging cells (18). Supernatant medium containing the
virus was harvested 24–48 h after transfection and used for
viral transduction.
Myeloid progenitor transformation assay
The myeloid progenitor transformation assay was per-
formed using cells harvested from the femurs and tibiae
of C57BL/6 mice. C-kit-positive cells were enriched using
magnetic beads conjugated with anti-c-kit antibody
(Miltenyi Biotech, Bergisch Gladbach, Germany),
transduced with recombinant retrovirus by spinoculation
(19) and plated in methylcellulose medium (Iscove’s
modified Dulbecco’s medium, 20% fetal bovine serum,
1.6% methylcellulose, 100 mM b-mercaptoethanol) con-
taining stem cell factor, interleukin-3 and granulocyte
macrophage colony-stimulating factor (10 ng/ml). The
colony-forming units per 104 plated cells at the third and
fourth rounds were quantified after 5–7 days of culture.
Subcellular fractionation and nucleosome
co-immunoprecipitation analysis
Subcellular fractions of 293T cells were obtained by CSK
buffer extraction (20) and MNase treatment. 293T cells
cultured in a 10-cm dish were resuspended in 1ml of
CSK buffer [100mM NaCl, 10mM PIPES (pH 6.8),
3mM MgCl2, 1mM EGTA (pH 7.6), 0.3M sucrose,
0.5% Triton X-100, 5mM sodium butyrate, 0.5mM
DTT, EDTA-free protease inhibitor cocktail (Roche,
Basel, Switzerland) and 2mM vanadyl ribonucleoside
complexes (Sigma, St. Louis, MO)], incubated on ice for
5min and then centrifuged (400g, 4C, 4min). The super-
natant (the soluble fraction) was transferred to a new tube,
and the pellet was resuspended in 1ml of MNase buffer
[50mM Tris-HCl (pH 7.5), 4mM MgCl2, 1mM CaCl2,
0.3M sucrose, 5mM sodium butyrate, 0.5mM DTT
and protease inhibitor cocktail]. One unit of MNase
(Sigma) was added to the suspension, and the mixture
was incubated at 37C for 10–12min to obtain
mononucleosomes. The MNase reaction was stopped by
adding EDTA (pH 8.0) at a final concentration of 20mM.
The reaction mixture was centrifuged (13 000 rpm, 4C,
5min) to separate the supernatant (the nucleosome
fraction) and the pellet. The pellet was resuspended in
elution buffer (1% sodium dodecyl sulfate, 50mM
NaHCO3). The nucleosome fractions were subjected
to immunoprecipitation (IP) using specific antibodies;
washed five times with MNase buffer with 20mM
EDTA and analyzed by western blotting, Oriole staining
(Bio-Rad, Hercules, CA), SYBR Green staining (Lonza,
Basel, Switzerland) and mass spectrometry. Optionally,
the precipitates were washed with MNase buffer three
times, treated with DNase I (Qiagen) for 10min at 37C
and washed five times with MNase buffer with 20mM
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EDTA. The precipitates were analyzed by western blotting
and SYBR Green staining.
Fractionation-assisted native chromatin
immunoprecipitation
293T cells cultured in a 10-cm dish or ML-2 cells (2 107)
were suspended in 1ml of CSK buffer to remove chroma-
tin-unbound materials. The pellet was then resuspended in
1ml of MNase buffer and mixed with 0.2–1U of MNase
for 5–10min at 37C to obtain chromatin with DNA
lengths of 150–3000 base pairs (bp). The MNase
reaction was stopped by adding EDTA (pH 8.0) at a
final concentration of 20mM, and then the mixture
was placed on ice. Lysis buffer (1ml) [10% glycerol,
20mM sodium phosphate (pH 7.0), 250mM NaCl,
30mM sodium pyrophosphate, 0.1% Nonidet P-40,
5mM EDTA, 10mM NaF and protease inhibitor
cocktail] (21) was added to solubilize the proteins, and
the mixture was spun down to remove insoluble
material. The supernatant was then subjected to IP.
Approximately 1 mg of the primary antibodies listed in
Supplementary Table S2 was added to 400ml of chromatin
suspension, and the mixture was incubated for 4–6 h at
4C. Ten microliters of protein-G magnetic beads
(Invitrogen) was added to each sample, and the mixture
was incubated for 2 h with rotation. The beads were
washed five times with 500ml of a 1:1 mixture of MNase
buffer containing 20mM EDTA and lysis buffer. For
histone modifications, incubation and washing were per-
formed with higher NaCl concentrations (plus 400mM) to
strip chromatin-binding proteins. DNAs were harvested
from the precipitates by dissolving in elution buffer
followed by phenol/chloroform/iso-amyl alcohol extrac-
tion and ethanol precipitation. Deep sequencing of the
precipitated DNAs was performed using the Illumina
genome analyzer IIx at the Joint Usage/Research Center
(RIRBM), Hiroshima University. qPCR was performed
on the precipitated DNAs using the custom-made primer
sets described in Supplementary Table S3. The value
relative to the input was determined using a standard
curve and the relative quantification method as described
in the ABI User Bulletin #2. Optionally, co-precipitated
proteins were harvested by dissolving the immunopre-
cipitates in elution buffer, mixed with an equal volume
of 2 sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis sample buffer and subjected to western blotting.
Liquid chromatography-tandem mass
spectrometry analysis
The method for trypsin digestion of protein has been
described previously (22). Tandem mass spectrometry
analysis was performed using an LTQ Orbitrap ELITE
ETD mass spectrometer (Thermo Fisher Scientific). The
methods used for liquid chromatography-tandem mass
spectrometry (LC-MS/MS) were slightly modified from
those described previously (23). The mass spectrometer
was operated in data-dependent acquisition mode in
which MS acquisition with a mass range of m/z 400–
1000 was automatically switched to MS/MS acquisition
under the control of Xcalibur software. The top four
precursor ions in the MS scan were selected by Orbitrap,
with resolution R=240 000, and those in the subsequent
MS/MS scans, with an ion trap in automated gain control
(AGC) mode, where AGC values were 1 106 and
1.00 104 for full MS and MS/MS, respectively. For frag-
mentation, electron transfer dissociation was used.
In vivo leukemogenesis assay
C-kit-positive cells (2 105) prepared from mouse femurs
and tibiae were transduced with retrovirus by
spinoculation and intravenously transplanted into
sublethally irradiated (two doses of 500 rad in 2 days)
C57BL/6 mice. Moribund mice were sacrificed, and the
spleen cells were either subjected to cytospin preparation
followed by May-Grunwald/Giemsa staining or tempor-
arily cultured in methylcellulose medium in the presence
of G418 (1mg/ml) to remove untransformed cells, and
then subjected to secondary transplantation or reverse
transcription-PCR (RT-PCR) analysis.
CpG island recovery assay
CpG island recovery assays for non-methylated CpGs
(CIRA) and methylated CpGs (MIRA) were performed
using the Unmethyl Collector kit and Methyl Collector
Ultra kit, respectively (Active Motif, Carlsbad, CA).
Deep sequencing after CIRA and MIRA was carried out
at the Joint Usage/Research Center (RIRBM), Hiroshima
University.
Transactivation assay
Transactivation assays using the pFR-luc reporter
(Clontech) were performed as described elsewhere (14).
Relative luciferase activities were normalized to Renilla
luciferase activity and expressed in terms of the average
values and standard deviations (SDs) of triplicate deter-
minations relative to the GAL4 DNA binding domain
controls.
RESULTS
Murine leukemia models define the major functional
modules required for leukemic transformation
by MLL-ENL
MLL fusion proteins form a trimeric complex with menin
and LEDGF through the MLL portion (7). Because MLL
fusion proteins associate with LEDGF through menin as a
mediator, an MLL-ENL mutant (MEdNter) lacking the
high-affinity menin-binding motif failed to transform
hematopoietic progenitors in a myeloid progenitor trans-
formation assay (Figure 1A), in which successful trans-
formation is represented by vigorous colony-forming
activity in the third and fourth rounds of plating, and
elevated expression of Hoxa9 in first-round colonies
(Figure 1B). An artificial MLL-ENL fusion protein
(PME), in which high-affinity menin-binding motif is
replaced by the PWWP domain of LEDGF, transformed
myeloid progenitors despite its inability to form the
trimeric complex (7). Therefore, the PWWP domain is
Nucleic Acids Research, 2014, Vol. 42, No. 7 4243
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Figure 1. Major functional domains required for leukemogenesis by MLL-ENL. (A) Experimental scheme for the myeloid progenitor transformation
assay. (B) Transforming ability of various MLL-ENL (ME) mutants. The schematic structures of LEDGF, MENIN, ENL and various ME mutants are
shown, with the key functional modules indicated (left). P: the PWWP domain. C: the CXXC domain. E: the ENL portion included in MLL-ENL. The
numbers of colony-forming units (CFUs) at the third and fourth rounds of replating are shown with error bars (SD of >3 independent experiments)
(middle). Hoxa9 expression is presented relative to the value of ME (arbitrarily set at 100%) with error bars (SD of triplicate PCRs) (right). (C) Protein
expression of the PWWP-MLL-ENL (PME) and PCE mutants in the packaging cells. The PME and PCE proteins were visualized using the anti-ENL
antibody. Molecular standards are shown on the left. (D) Experimental scheme for the in vivo leukemogenesis assay. (E) Survival of the transplanted
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the single functional module within menin and LEDGF
that is required for MLL-ENL-dependent transformation.
To identify the structural requirements of MLL fusion
proteins besides the PWWP domain, we examined the
transforming ability of a series of PME mutants with
various internal deletions in the MLL gene. A mutant
lacking the CXXC domain (PMEdC) failed to transform
myeloid progenitors (Figure 1B and C). Conversely, a
mutant (PCE) consisting only of the PWWP domain, the
CXXC domain and the ENL portion activated Hoxa9
expression and immortalized myeloid progenitors. The
PCE mutant induced leukemia in recipient mice within
3–4 months in the in vivo leukemogenesis assay
(Figure 1D–F). The PCE-induced leukemic blasts had
monocytic features (Figure 1G) and elevated expression
of posterior Hoxa genes and leukemia stem cell signature
genes including Myb, Hmgb3 and Cbx5 (Supplementary
Figure S1), which are major characteristics of MLL-
associated myeloid leukemias (24). The leukemic blasts
recapitulated the same disease in secondary recipients
with a much shorter latency period (Figure 1E). These
results clearly show that PCE is as functional as MLL-
ENL for leukemic transformation. Thus, the PWWP
domain, the CXXC domain and the ENL portion
are the major structural elements required for MLL-
associated leukemogenesis.
Binding to a specific nucleosome through the PWWP
domain is essential for MLL fusion-dependent
gene activation
To further analyze the function of the PWWP domain, we
next tested a series of artificial PCE derivatives with
various alterations in the PWWP domain for the trans-
forming ability of myeloid progenitors (Figure 2A and
B). A mutant (P0CE) with the minimum structure of the
PWWP domain exhibited this transformation ability,
whereas an alanine substitution of the evolutionarily
conserved tryptophan (W21) resulted in a loss of the trans-
formation activity. The PWWP domain of LEDGF has
been implicated in chromatin binding (25,26). To examine
its chromatin-binding capacity, we transiently expressed
LEDGF and its mutant (dPWWP) lacking the PWWP
domain in 293T cells (Figure 2C), and we divided the
cellular components into three subfractions (Figure 2D
and Supplementary Figure S2A). In this procedure,
(i) chromatin-unbound soluble materials were extracted
by cytoskeletal (CSK) buffer (the soluble fraction);
(ii) chromatin and its associated factors were eluted by
DNA fragmentation with micrococcal nuclease (MNase)
(the nucleosome fraction); and (iii) insoluble materials
after MNase treatment were solubilized by denaturing
detergent (the nuclear matrix fraction). Nearly all the
nucleosomes in the nucleosome fraction were
mononucleosomes based on their DNA length (150 bp)
(Figure 2E, top panels). LEDGF substantially localized to
the nucleosome fraction (Figure 2E, bottom panels) and
was able to pull down mononucleosomes (Figure 2F),
whereas dPWWP mainly localized to the soluble
fraction (Figure 2E) and failed to pull down nucleosomes
(Figure 2F). The PWWP domain (P0) by itself localized in
the nucleosome fraction (Figure 2G and H) and pulled
down endogenous nucleosomes (Figure 2I). Previously,
one group showed that LEDGF had specifically
associated with the histone H3 peptide containing
either H3K36me2 or H3K36me3 (25), while another
group showed that the recombinant PWWP domain of
LEDGF directly binds to H3K36me3 but not to
H3K36me2 in vitro (26), suggesting that the peptide pull-
down assay tends to overrepresent H3K36me3–PWWP
interaction, depending on the assay conditions. Our
nucleosome co-immunoprecipitation (co-IP) assay, which
can detect protein–nucleosome interaction under physio-
logical conditions, showed that the nucleosomes co-
precipitated with P0 contained high amounts of not only
H3K36me3 but also H3K36me2 (Figure 2I), indicating
that the PWWP domain of LEDGF is capable of
binding to either H3K36me2 or H3K36me3 in vivo.
In accordance with these results, an artificial protein
(P0C) composed of the PWWP domain and the CXXC
domain was substantially localized in the nucleosome
fraction (Figures 2G and H) and co-precipitated with
mononucleosomes and DNAs (Supplementary Figure
S2B and C). The W21A substitution mutants of P0
and P0C exclusively localized to the soluble fraction
(Figures 2G and H) and therefore were not used for the
nucleosome co-IP analysis (Supplementary Figures S2D
and E). These results indicate that the PWWP domain,
and not the CXXC domain, is mainly responsible for
stable association with chromatin. The purified P0C–
nucleosome complex contained no other proteins but
histones at the stoichiometric level (Supplementary
Figure S2B). Complete removal of the DNAs by
DNase I treatment did not abolish the P0C–nucleosome
interaction (Figure 2J) or P0–nucleosome interaction
(Supplementary Figure S2F). Thus, the PWWP domain
directly associates with histones. Taken together, these
findings show that the binding ability of the PWWP
domain to specific histones is required for MLL fusion-
dependent gene activation.
The PWWP domain and the CXXC domain target
transcriptionally active promoters containing either
H3K36me2 or H3K36me3
We next examined the functional similarities among
various PWWP domains. HRP2 is a close homolog
of LEDGF and has a highly homologous PWWP
domain (Figure 3A). The bromodomain and PHD
finger-containing 1 (BRPF1) protein is an associated
Figure 1. Continued
animals in the in vivo leukemogenesis assay. Light gray, vector; black, first PCE transplantation; dark gray, second PCE transplantation. n, number
of animals analyzed. (F) Expression of PCE in the PCE-induced leukemia cells (PCE-LCs). Leukemic cells derived from moribund mice were cultured
ex vivo in the presence of G418 and analyzed by RT-PCR. The PCE plasmid, PCE-immortalized cells (PCE-ICs) and Bcl2/E2A-HLF-immortalized
cells (BiEH-ICs) were included for comparison. nsp, non-specific band. (G) Morphology of PCE-LCs in the spleen. The splenic cells harvested from a
PCE-leukemic mouse were stained by the May-Grunwald/Giemsa staining method. Normal spleen is included for comparison. Scale bar, 50 mm.
Nucleic Acids Research, 2014, Vol. 42, No. 7 4245
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Figure 2. Nucleosome binding by the PWWP domain is essential for MLL-ENL-dependent transformation. (A) Transforming ability of PCE
mutants containing various mutations within the PWWP domain. P0: the minimum structure of the PWWP domain. The schematic structures of
LEDGF and various PCE mutants are shown (left). The CFUs at the third and fourth rounds of replating are shown with error bars (SD of >3
independent experiments) (middle). Hoxa9 expression in the first-round colonies is expressed relative to that of PCE (arbitrarily set at 100%) with
error bars (SD of triplicate PCRs) (right). (B) Protein expression of the PCE mutants in the packaging cells. The PCE mutant proteins were
visualized using the anti-ENL antibody. (C) The schematic structures of LEDGF and its mutant lacking the PWWP domain (dPWWP). An Xpress
tag (gray flag) is fused to the N-terminal end of the LEDGF proteins. Their ability to associate with nucleosomes is summarized. (D) Experimental
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factor of the MOZ histone acetyltransferase (27) and has a
less conserved PWWP domain, which has been recently
shown to directly bind to histone H3 peptide containing
H3K36me2 or H3K36me3 in vitro (28). To investigate the
functional differences and similarities of the PWWP
domains of LEDGF, HRP2 and BRPF1, we tested
whether these PWWP domains are interchangeable in
the myeloid progenitor transformation assay. The P0CE
mutants whose PWWP domain is replaced by those of
HRP2 and LEDGF successfully activated Hoxa9 expres-
sion and immortalized myeloid progenitors (Figure 3A
and B). Nucleosome co-IP assay with the P0C mutants
containing the PWWP domains of LEDGF and BRPF1
specifically enriched nucleosomes containing H3K36me2
more efficiently than those containing H3K36me3
(Figure 3C and D). Consistent with these results, mass
spectrometry analysis indicated that two-thirds of
P0C-bound nucleosomes contained the H3K36me2
marker, while the H3K36me3 marker was minor
compared with P0-bound nucleosomes (Supplementary
Figure S3). In addition, chromatin modifications charac-
teristic to active promoters such as di-methylated histone
H3 lysine 4 (H3K4me2) (Figures 2I and 3D), acetylated
histone H3 lysine 9 (H3K9ac) and acetylated histone H3
lysine 27 (H3K27ac) (Supplementary Figure S3) were
enriched in P0C-bound nucleosomes, suggesting that the
CXXC domain confers affinity toward active promoters.
To determine the targeting ability of these artificial
proteins to known MLL target genes in vivo, we per-
formed chromatin immunoprecipitation (ChIP) followed
by qPCR on 293T cells transiently expressing those P0C
mutants (Figure 3C and E). To this end, we devised a
highly sensitive native ChIP protocol by altering the afore-
mentioned nucleosome IP protocol. In this ChIP method,
we resuspended the cells in CSK buffer to remove the
chromatin-unbound materials and treated the cells with
MNase to digest the DNAs to achieve the average
length of 500–1000 bp. The highly solubilized chromatin
fraction was extracted with lysis buffer and then subjected
to IP. We designated this protocol fractionation-assisted
native ChIP, but hereafter it is referred to as ChIP.
Ecotropic viral integration site 1 (EVI1), paired-like
homeodomain transcription factor 2 (PITX2), HOXA7
and HOXA9 were previously reported as potential MLL
target genes (14,28–30). Although the chromatin environ-
ment in 293T cells might be different from that in
leukemia cells, the P0C mutants, but not P0(W21A)C,
were localized at the transcription start sites (TSSs)
of PITX2, HOXA7 and HOXA9, but not EVI1
(Figure 3E). These genes showed enrichment of
H3K4me2 near the TSS, consistent with the observation
that P0C-bound nucleosomes contain high levels of
H3K4me2 modification (Figure 3D–F). H3K36me2 was
present in all of the P0C mutant-occupied loci, while
H3K36me3 was only found at the HOXA9 locus
(Figure 3F), supporting the notion that the PWWP
domain binds either H3K36me2 or H3K36me3 in vivo.
The presence of RNA polymerase II (RNAPII) indicated
that PITX2, HOXA7 and HOXA9, but not EVI1, were
transcriptionally active in 293T cells (Figure 3F). Thus,
the PWWP domain and the CXXC domain collabora-
tively target the promoter-proximal regions of transcrip-
tionally active genes containing either H3K36me2 or
H3K36me3.
The chromatin context comprising H3K36me2/3 and
non-methylated CpGs is targeted by MLL fusion proteins
Next, we examined the structural requirements of the
CXXC domain. A deletion mutant (P0C0E) that lacks the
sequences flanking the CXXC domain successfully trans-
formed myeloid progenitors (Figure 4A and B). Therefore,
the CXXC domain, but not its flanking sequences, is
required for the proper targeting of MLL-ENL. The
CXXC domain of MLL directly binds to non-methylated
CpGs (31–34). Point mutations that have been proved to
abolish the binding ability to non-methylated CpGs
(C1155A and K1186A) (31) resulted in a loss of transform-
ing activity (Figure 4A and B), while the Q1162A substitu-
tion, which has no effect on non-methylated CpG-specific
binding, did not compromise transformation. Mutations in
the KFGG motif (K1178A and K1179A) that severely at-
tenuate the binding ability to non-methylated CpGs (31)
also abolished transforming activity. The artificial protein
(P0C0) composed of the minimum structures of the PWWP
domain and the CXXC domain localized in the nucleosome
fraction (Figure 4C and D) and associated with nucleo-
somes (Figure 4E). The P0C0 mutants carrying CpG
binding-deficient mutations retained the nucleosome
Figure 2. Continued
scheme of subcellular fractionation. (E) Distribution of DNAs/RNAs (top) and LEDGF proteins (bottom) in the three subfractions. 293T cells
transiently expressing the indicated proteins were subfractionated into the soluble fraction (SOL), the nucleosome fraction (NUC) and the nuclear
matrix fraction (NM). The LEDGF proteins were visualized using anti-Xpress antibody. (F) Nucleosomes associated with LEDGF and dPWWP.
Nucleosome co-IP assay was performed with the nucleosome fractions of 293T cells transiently expressing the LEDGF proteins. The LEDGF mutant
proteins and histone H3 proteins were visualized using anti-Xpress and histone H3 antibodies, respectively. (G) The schematic structures of the P0
and the P0C mutants. An Xpress tag (gray flag) is fused to the N-terminal end of P0 mutants. A FLAG tag (black flag) is fused to the C-terminal end
of the P0C mutants. The localization to the nucleosome fraction of each mutant and its ability to bind nucleosomes are summarized. N.A., not
applicable. (H) Subcellular distribution of the P0 and P0C mutants. Experiments were performed as in (E). The P0 mutants were visualized by using
the anti-Xpress antibody. The P0C mutants were visualized by using the anti-FLAG antibody. (I) Nucleosomes associated with P0. P0 and its
associating nucleosomes were co-purified by co-IP from the NUC fraction of 293T cells transiently expressing P0 as in (F). Nucleosomes were
visualized by antibodies specific for mono-methylated histone H3 lysine 36 (H3K36me1), H3K36me2 and H3K36me3 or by anti-histone H2B and
-H3 antibodies. Di-methylated histone H3 lysine 4 (H3K4me2), tri-methylated histone H3 lysine 27 (H3K27me3) and acetylated histone H3 lysine 27
(H3K27ac) were also analyzed for comparison. (J) The role of DNAs in P0C–nucleosome interaction. P0C and its associating nucleosomes were co-
purified by co-IP using the anti-FLAG antibody from the NUC fraction of 293T cells expressing P0C. The precipitates were treated with or without
DNase I (300 kU/ml) for 10min and washed to remove unbound material. DNAs co-precipitated with P0C were visualized by SYBR Green staining.
Nucleosomes were visualized by antibodies specific for H3K36me2 and H3K36me3 modification or by the anti-histone-H3 antibody.
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                         #
LEDGF   6-KPGDLIFAKMKGYPHWPAR-VDEVPDGAVKPPTNKLPIFFFGTHETA-FLGPKDIFPYSEN--KEKYGKPNKRK-75
HRP2    6-KPGDLVFAKMKGYPHWPAR-IDDIADGAVKPPPNKYPIFFFGTHETA-FLGPKDLFPYDKC--KDKYGKPNKRK-75
BRPF1 1091-ALDLVWAKCRGYPSYPALIIDPKMPREGM(30aa)LVLFFDNKRTWQWLPRTKLVPLGVNQDLDKEKMLEGRK-1185
             **  **  ***  **   *                 **    *   *      *        *      ** 
3rd
4th
Figure 3. The PWWP domain and the CXXC domain target active promoters containing H3K36me2/3 in vivo. (A) Transforming ability of P0CE
mutants containing three different PWWP domains. The schematic structures of LEDGF, HRP2, BRPF1 and various P0CE mutants are shown (left).
Sequence alignment of the three PWWP domains is shown. Asterisk, conserved residue. The tryptophan residue mutated in Figure 2A is indicated by
#. The CFUs at the third and fourth rounds of replating are shown with error bars (SD of >3 independent experiments) (middle). Hoxa9 expression
in the first-round colonies is expressed relative to that of P0CE (arbitrarily set at 100%) with error bars (SD of triplicate PCRs) (right). (B) Protein
expression of the P0CE mutants carrying non-LEDGF PWWP domains in the packaging cells. The P0CE mutant proteins were visualized using the
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binding activity because they had an intact PWWP domain
(Figure 4C–E). To investigate the CpG methylation status
of the MLL target genes, we performed CIRA using the
recombinant CXXC domain protein followed by qPCR,
which showed that PITX2, HOXA7 and HOXA9 loci con-
tained ample amounts of non-methylated CpGs near the
TSSs in 293T cells (Figure 4F). ChIP-qPCR analysis of
293T cells transiently expressing these P0C0 mutants
showed that only the wild-type control, not the CpG
binding-deficient mutants, was able to associate with the
promoters of MLL target genes (Figure 4G). Thus,
binding to non-methylated CpGs through the CXXC
domain is essential for the proper targeting of MLL
fusion proteins.
There are dozens of CXXC domain-containing proteins
in mammals. To examine the functional similarity of dif-
ferent CXXC domains, we generated several domain swap
mutants of P0C0E whose CXXC domain is replaced by
other CXXC domains (Figure 5A and B). The CXXC
domains of MLL2 (also known as HRX2, MLL4 and
KMT2B) (35), DNA (cytosine-5)-methyltransferase 1
(DNMT1) (36) and F-box and leucine-rich repeat
protein 11 (FBXL11; also known as KDM2A) (37) were
previously shown to bind to non-methylated CpGs. P0C0E
mutants carrying these three non-MLL CXXC domains
were competent for leukemic transformation (Figure 5A
and B). Furthermore, the P0C0 mutant with the CXXC
domain of FBXL11 (Figure 5C and Supplementary
Figure S4) was able to associate with MLL target genes
in 293T cells (Figure 5D). These results indicate that the
three different CXXC domains are functionally equivalent
in terms of MLL-dependent gene activation, confirming
the notion that the binding ability to non-methylated
CpGs, a common function of those three CXXC
domains, is required for targeting of MLL fusion proteins.
Taken together, the minimum functional modules
required for the targeting of MLL fusion protein are the
PWWP domain and the CXXC domain, which bind to
nucleosomes with H3K36me2/3 and non-methylated
CpGs, respectively. Therefore, the MLL fusion complex
targets a chromatin context in which H3K36me2/3 and
non-methylated CpGs coexist.
The MLL-AF6 complex localizes at transcriptionally
active promoters containing H3K36me2/3 and
non-methylated CpGs in vivo
To determine the genomic landscape of the MLL target
genes under physiological conditions, we performed a
genome-wide ChIP analysis of cells that express an
MLL fusion protein endogenously. ML-2 cells express
MLL-AF6, but not wild-type MLL (38,39); therefore,
the ChIP signal obtained from ML-2 cells using the anti-
MLL antibody can be ascribed to the presence of MLL-
AF6. Our ChIP analysis followed by deep sequencing
(ChIP-seq) using the anti-MLL antibody identified 154
TSSs of 131 MLL-AF6 target genes (Supplementary
Table S1) by virtue of enriched ChIP signals of MLL-
AF6 near the TSSs. These regions included previously
identified MLL target genes such as HOXA9, HOXA10,
cyclin-dependent kinase inhibitor 1B (CDKN1B),
CDKN2C, transcription factor 4 (TCF4) and runt-related
transcription factor 2 (RUNX2) (14,40), and some newly
identified genes such as special AT-rich sequence-binding
protein-1 (SATB1), ribosomal protein L31 (RPL31)
and RPL10A (Supplementary Figure S5A and
Supplementary Table S1). Gene ontology analysis of
these MLL-AF6 target genes indicates that MLL-AF6
mainly associates with genes involved in gene expression
and translation (Supplementary Figure S5B). The average
distribution of MLL-AF6 at the MLL target loci indicates
that MLL-AF6 localizes near the TSSs (Figure 6A). MLL
target loci contain a relatively large amount of CpG
sequence near the TSSs. CIRA and MIRA followed by
deep sequencing (CIRA-seq and MIRA-seq respectively)
showed that MLL target loci are rich with non-methylated
CpGs but are devoid of methylated CpGs. MLL-AF6-
occupied loci also exhibited an enrichment of RNAPII
and H3K36me3 (Figure 6A and Supplementary Figure
S5C). Thus, endogenously expressed MLL-AF6 specific-
ally localizes at CpG-rich promoters of transcriptionally
active genes.
ChIP-qPCR and CIRA-qPCR analyses on each gene
confirmed that the MLL-AF6 complex localized at the
major MLL target loci including HOXA7, CDKN2C,
CDKN1B and HOXA9 but was completely absent at the
gene loci of PITX2 and MEIS1, which are potentially
regulated by MLL (14) but are transcriptionally inactive
in this cell line (Figure 6B and C and Supplementary
Figure S5D and E). MLL-AF6, menin and LEDGF
co-localized near the TSSs of MLL target genes where
non-methylated CpGs are abundant (Figure 6B and
Supplementary Figure S5D). H3K36me2 was ubiquitously
present and relatively enriched at the transcriptionally active
loci. The MLL-AF6 complex localized at the promoter-
proximal regions of HOXA7 and CDKN2C, which were
H3K36me2-rich but H3K36me3-poor (Figure 6B and C).
On the other hand, the MLL-AF6 complex was highly
enriched near the TSS of HOXA9, where H3K36me2 was
scarce but H3K36me3 was abundant (Figure 6B and C and
Supplementary Figure S5D and E). These results confirm
Figure 3. Continued
anti-ENL antibody. (C) The schematic structures of various P0C mutants. A FLAG tag (black flag) is fused to the C-terminal end of the P0C
mutants. Their abilities to bind nucleosomes and target promoters are summarized. (D) Nucleosomes associated with the P0C mutants. The P0C
mutants and their associating nucleosomes were co-purified by co-IP using the anti-FLAG antibody from the NUC fraction of 293T cells transiently
expressing the P0C mutants. Nucleosomes were visualized by antibodies specific for histone H3 or the indicated modifications. Nucleosomes co-
purified with FLAG-tagged histone H4 were also analyzed for comparison. (E) Chromatin targeting ability of the P0C mutants. Genomic localization
of the P0C mutants was analyzed by ChIP using the anti-FLAG antibody in 293T cells transiently expressing the P0C mutants. The precipitated
DNAs were analyzed by qPCR using specific probes for pre-TSS (1.0 to 0.5 kb of TSS), TSS (0 to+0.5 kb of TSS) and post-TSS (+1.0 to 1.5 kb
of TSS) of the indicated genes. (F) Epigenetic status of MLL target genes in 293T cells. ChIP analysis was performed on 293T cells using antibodies
specific for H3K36me2, H3K36me3, H3K4me2 and RNAPII. The precipitated DNAs were analyzed by qPCR as in (E).
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Figure 4. MLL-ENL recognizes the chromatin context with H3K36me2/3 and non-methylated CpGs. (A) Transforming ability of P0CE mutants
with various mutations within the CXXC domain. The schematic structures of MLL and various P0CE mutants are shown (left). C0: the minimum
structure of the CXXC domain; C0+, the minimum structure of the CXXC domain and its C-terminal flanking region. Their ability to bind to non-
methylated CpGs is summarized. The CFUs at the third and fourth rounds of replating are shown with error bars (SD of >3 independent
experiments) (middle). Hoxa9 expression in the first-round colonies is expressed relative to the value of P0CE (arbitrarily set at 100%) with error
bars (SD of triplicate PCRs) (right). (B) Protein expression of the P0CE mutants in the packaging cells. The P0CE mutant proteins were visualized by
the anti-ENL antibody. (C) The schematic structures of various P0C0 mutants. A FLAG tag (black flag) is fused to the C-terminal end of the P0C0
mutants. Their abilities to bind non-methylated CpGs, nucleosomes and target promoters are summarized. (D) Subcellular distribution of the P0C0
mutants. Experiments were performed as in Figure 2E. The P0C0 mutants were visualized by the anti-FLAG antibody. (E) Nucleosomes associated
with the P0C0 mutants. The P0C mutants and their associating nucleosomes were analyzed as in Figure 2F. (F) Distribution of non-methylated CpGs
at the MLL target genes. Genomic DNAs of 293T cells were analyzed by CIRA. The precipitated DNAs were analyzed by qPCR as in Figure 3E.
(G) Chromatin targeting ability of the P0C mutants. Genomic localization of the P0C0 mutants was analyzed by ChIP as in Figure 3E.
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the notion that the presence of either H3K36me2 or
H3K36me3 is required for targeting of the MLL fusion
complex. Hence, our data strongly indicate that the MLL-
fusion complex targets the promoter-proximal regions con-
taining H3K36me2/3 and non-methylated CpGs under
physiological conditions.
It should be noted that the MLL fusion complex was
also found by ChIP-qPCR at a housekeeping gene,
glyceraldehyde phosphate dehydrogenase (GAPDH),
whose promoter-proximal region also contained
H3K36me2/3 and non-methylated CpGs near the TSS
(Figure 6B and Supplementary Figure S5D). However,
the localization of the MLL-AF6 complex was much
weaker than that at well-known MLL target genes.
These results suggest that the extent of occupation by
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                        #      #               ##      #
Hs MLL   1145-PVKKGRRSRRCGQCPGCQVPEDCGVCTNCLDKPKFGGRNIKKQCCKMRKCQ-NLQWM-1200
Hs MLL2   957-HGKKM-RMARCGHCRGCLRVQDCGSCVNCLDKPKFGGPNTKKQCCVYRKCDKIEARK-1012
Rn DNMT1  648-KENTMKR-RRCGVCEVCQQPE-CGKCKACKDMVKFGGTGRSKQACLKRRCP-NLAVK-701
Hs FBXL11 560-VSGARRRRVRCRKCKACVQGE-CGVCHYCRDMKKFGGPGRMKQSCVLRQCLAPRLPH-616

























Figure 5. Non-MLL CXXC domains can functionally substitute for the MLL CXXC domain. (A) Transforming ability of P0C0E mutants
with various non-MLL CXXC domains. The schematic structures of MLL, MLL2, DNMT1, FBXL11 and various P0C0E mutants are shown
(left). Sequence alignment of the CXXC domains of MLL, MLL2, DNMT1 and FBXL11. The mutated residues in Figure 4A are indicated by
#. Asterisk, conserved residue. The CFUs at the third and fourth rounds of replating are shown with error bars (SD of >3 independent experiments)
(middle). Hoxa9 expression in the first-round colonies is expressed relative to the value of P0C0E (arbitrarily set at 100%) with error bars (SD of
triplicate PCRs) (right). (B) Protein expression of the P0C0E mutants carrying non-MLL CXXC domains in the packaging cells. The P0C0E mutant
proteins were visualized by the anti-ENL antibody. (C) The schematic structure of the P0C0 mutant carrying the CXXC domain of FBXL11
[P0C0(FBXL11)]. A FLAG tag is fused to the C-terminal end of the CXXC domain (black flag). Its ability to associate with the tar-
get promoters is indicated. (D) Chromatin targeting ability of P0C0(FBXL11). Genomic localization of P0C0(FBXL11) was analyzed by ChIP as
in Figure 3E.
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Figure 6. Genomic landscape of MLL-AF6 target genes in ML-2 cells. (A) The average distribution of MLL-AF6, RNAPII, CpG dinucleotide, non-
methylated CpGs and methylated CpGs at the 154 MLL-AF6-occupied TSSs. The input data and all TSS data are included for comparison. ChIP-
seq or CIRA/MIRA-seq tags were clustered into 100-bp bins. On the x axis, the position of the associated TSS is designated as 0 bp. The y axis
indicates the normalized ChIP-seq tag count (ppm). The average number of CpG dinucleotide in each bin was also plotted. (B) Genomic localization
of MLL-AF6, LEDGF, non-methylated CpGs, H3K36me2, H3K36me3 and RNAPII in ML-2 cells at various gene loci. Genomic localization was
determined by ChIP-qPCR or CIRA-qPCR. The precipitated DNAs were analyzed using the specific probes for pre-TSS (1.0 to 0.5 kb of TSS),
TSS (0 to +0.5 kb of TSS) and post-TSS (+1.0 to 1.5 kb of TSS) of the indicated genes. (C) Genomic localization of MLL-AF6, LEDGF, non-
methylated CpGs, H3K36me2, H3K36me3 and RNAPII in ML-2 cells at the posterior HOXA loci. Relative locations of the HOXA6, HOXA7 and
HOXA9 loci are shown at the bottom.
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Figure 7. MLL fusion-dependent gene activation is mediated by AF4-family coactivators. (A) Transforming ability of P0C0+ mutants fused with
ENL and AF5q31. The schematic structures of ENL, AF5q31 and various P0C0+mutants are shown (left). An HA tag (white flag) is fused to the
C-terminal end of the P0C0+ structure. E dAHD:the ENL portion lacking the ANC1 homology domain (AHD). E0: the minimum transformation
domain of ENL composed of AHD. The CFUs at the third and fourth rounds of replating are shown with error bars (SD of >3 independent
experiments) (middle). Hoxa9 expression in the first-round colonies is expressed relative to the value of P0C0+E (arbitrarily set at 100%) with error
bars (SD of triplicate PCRs) (right). (B) Protein expression of the P0C0+mutants fused with ENL and AF5q31 in the packaging cells. The P0C0+
mutant proteins were visualized by the anti-HA antibody. (C) Association of AHD and the AF4-family proteins. A series of FLAG-tagged GAL4-
ENL fusion proteins (Supplementary Figure S6) were transiently expressed in 293T cells and subjected to ChIP using the anti-FLAG antibody. The
precipitates were analyzed by western blotting using the anti-FLAG and anti-AF5q31 antibodies. (D) Transcriptional activation activity of AHD.
A FLAG-tagged GAL4 DNA binding domain fused with AHD (GAL4-E0) was transiently expressed in 293T cells with the pFR-luc reporter plasmid
(5 GAL4 binding sequences and a TATA box are placed in front of the luciferase gene) and subjected to luciferase assay. Error bars represent the SD
of triplicate analyses. (E) Survival of the transplanted animals in the in vivo leukemogenesis assay. Gray, vector; black, P0C0+E. n, number of animals
analyzed. (F) Models of MLL-ENL-dependent gene activation.
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amounts of H3K36me2/3 and non-methylated CpGs
but also by other factors or environments that are yet
undetermined.
An interaction domain for AF4-family coactivators and
the targeting modules are the minimum elements required
for MLL-ENL-dependent leukemogenesis
Next, we analyzed the structural requirements of the
fusion partner portion. We tested the transforming
ability of various fusion partners that were fused with
the minimum targeting structure (P0C0+) composed of
the PWWP domain and the CXXC domain (the
C-terminal flanking sequence of the CXXC domain was
included to increase the protein stability). An artificial
protein (P0C0+E0) composed of the minimum targeting
structure and the ANC1 homology domain (AHD) of
ENL activated Hoxa9 expression and transformed
myeloid progenitors, whereas a P0C0+E mutant lacking a
part of AHD failed to transform myeloid progenitors
(Figure 7A and B). AHD is a binding platform for AF4
family transcriptional coactivators (14). Indeed, the GAL4
DNA binding domain fused with AHD (GAL4-E0)
associated with AF5q31 (also known as AFF4 and
MCEF) (Figure 7C and Supplementary Figure S6),
which is a member of the AF4 family, and exhibited tran-
scriptional activation activity (Figure 7D). Removing
AHD from P0C0+E0 resulted in the loss of transforming
ability (Figure 7A and B), whereas adding back the
AF5q31 portion restored the transforming ability,
indicating that association with the AF4-family
coactivator is essential for MLL-ENL-dependent trans-
formation. In vivo leukemogenesis assay showed that
P0C0+E0 induced leukemia in vivo (Figure 7E). Therefore,
the PWWP domain, the CXXC domain and AHD are the
minimum essential structures required for leukemic trans-
formation. Taken together, these results show that MLL
fusion proteins target the promoter-proximal regions
of transcriptionally active CpG-rich genes through dual
recognition of epigenetic markers and activate transcrip-
tion by recruiting transcriptional coactivators such as
AF4-family proteins (Figure 7F).
DISCUSSION
This study demonstrates that MLL fusion proteins tar-
get the promoter-proximal regions of previously active
genes by simultaneously recognizing H3K36me2/3 and
non-methylated CpGs and activate transcription by re-
cruiting transcriptional coactivators. Our structure–
function analysis demonstrated that an MLL-ENL
mutant composed only of the PWWP domain, the
CXXC domain and AHD was able to activate Hoxa9 ex-
pression and transform myeloid progenitors. These results
imply that the PWWP domain and the CXXC domain are
the only structures essentially required for target recogni-
tion by MLL fusion proteins. The PWWP domain specif-
ically binds to either H3K36me2 or H3K36me3, both of
which are indicators of active transcription. The CXXC
domain binds to non-methylated CpGs, which are clus-
tered in the active gene promoters. HOX loci are
enriched with CpGs and are therefore preferentially sub-
jected to MLL fusion-dependent gene activation. Our
ChIP/CIRA analyses showed that the MLL fusion
complex localizes at the promoter-proximal region,
where non-methylated CpGs and H3K36me2/3 are
present. Thus, dual recognition of the two epigenetic
markers is the major determinant for MLL fusion
proteins to identify their target genes. AHD is the
platform to recruit AF4 family transcriptional
coactivators, which confer transcriptional activation
activity. The fundamental mechanism of MLL fusion-
dependent gene activation is threefold: (i) LEDGF scans
the genome and binds to H3K36me2/3 through the
PWWP domain. (ii) The MLL fusion/menin complex
binds to non-methylated CpGs in the promoter through
the CXXC domain and a nearby chromatin-bound
LEDGF. These two points of contact allow the MLL
fusion complex to stably associate with its target chroma-
tin. (iii) The MLL fusion complex activates transcription
by recruiting transcriptional coactivators (Figure 7F).
However, it should be noted that these three domains
are the minimum elements, not all the elements, involved
in MLL fusion-dependent leukemogenesis in the context
of a full-length MLL fusion protein. The activity of the
MLL fusion complex is likely regulated through intricate
regulatory mechanisms. Factors that modulate its
function may also play critical roles in MLL fusion-
dependent leukemogenesis.
Aberrant self-renewal is an essential feature of
oncogene-driven proliferation. It requires the continuous
expression of a gene set that is required for self-renewal
through rounds of cell divisions; however, its mechanisms
are largely unclear. Because the PWWP and CXXC
domains are sufficient for target recognition, the MLL
fusion complex identifies posterior HOXA genes by a
chromatin context-dependent mechanism rather than by
mediating sequence-specific transcription factors. The
H3K36me3 marker is generally deposited into chromatin
in a transcriptional elongation-coupled manner by the
SETD2 methyltransferase (also known as KMT3A,
HYPB and SET2), which associates with actively
elongating RNAPII (41–43). The H3K36me2 marker is de-
posited into chromatin by various SET domain-containing
proteins, including NSD2, and is generally linked to tran-
scriptional activation (16). Hence, previously transcribed
genes containing H3K36me2/3 and non-methylated CpGs
at the promoter-proximal regions are subject to gene
activation by MLL fusion proteins. Consequently, the ex-
pression of previously transcribed HSC program genes is
maintained at high levels through rounds of cell division
to cause aberrant self-renewal.
In summary, our study identifies the minimum struc-
tural requirements of MLL fusion proteins for HOX
gene activation and reveals the chromatin context
recognized by them. A surprisingly simple combination
of epigenetic markers that defines previously active gene
promoters is used in MLL fusion-dependent cellular
memory maintenance. Thus, our results provide signifi-
cant insights into the molecular mechanisms of cellular
memory maintenance and aberrant self-renewal caused
by MLL fusion proteins.
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We generated ChIP-seq and CIRA/MIRA-seq data in this
study. Mass data obtained in this study have been
deposited under accession numbers DRA000555,
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Bank of Japan) Sequence Read Archive.
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